CTKB
Cytek Biosciences Inc
5.70$
+0.9%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 43.4% | 43.2% | 48.7% | 45.4% | 43.7% | 41.5% | 51.4% | 47.7% | 47.3% | 47.1% | 51.8% | 41.1% | 46.8% | |
| 56.6% | 56.8% | 51.3% | 54.6% | 56.3% | 58.5% | 48.6% | 52.3% | 52.7% | 52.9% | 48.2% | 58.9% | 53.2% | |
| 23.3% | 18.7% | 21.8% | 21.5% | 19.2% | 16.9% | 23.5% | 19.4% | 17.1% | 14.4% | 21.8% | 20.2% | 18.0% | |
| 21.6% | 18.5% | 25.4% | 25.1% | 21.2% | 15.8% | 31.1% | 29.7% | 30.8% | 26.4% | 41.8% | 35.0% | 32.8% | |
| 70.0% | 57.0% | 75.2% | 72.9% | 64.6% | 53.4% | 84.7% | 75.6% | 70.3% | 61.9% | 90.0% | 82.6% | 74.8% | |
| -13.4% | -0.2% | -23.9% | -18.3% | -8.2% | 5.2% | -36.1% | -23.3% | -17.6% | -9.0% | -41.8% | -23.7% | -21.6% | |
| 1.2% | 0.7% | 1.0% | 0.3% | 0.2% | 1.2% | 0.7% | 0.9% | 0.9% | 1.2% | 0.6% | 0.6% | 0.9% | |
| -8.7% | 7.1% | -20.0% | -15.4% | 0.3% | 18.0% | -27.2% | -14.9% | -14.9% | -6.5% | -39.4% | -24.2% | -19.7% | |
| 4.7% | -2.4% | -6.3% | 7.0% | -1.5% | 1.2% | 0.3% | -2.6% | -4.4% | 64.4% | 3.4% | 1.1% | 19.2% | |
| -13.5% | 9.4% | -13.8% | -22.4% | 1.8% | 16.8% | -27.5% | -12.2% | -10.5% | -70.9% | -42.7% | -25.3% | -39.0% | |
| -2.1% | 11.9% | -13.6% | -9.8% | 6.0% | -4.3% | -19.5% | -7.4% | -8.1% | -0.4% | -32.4% | -17.4% | -13.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.